Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Annovis Bio

ANVS

1.3056.12% ( -0.085 )

Trading: Sep 8, 14:57:29 (EDT)

OverviewOverview OptionsOptions NewsNews PostsPosts FinancialsFinancials ForecastForecast ValuationValuation ShareholdersShareholders ProfileProfile

LongbridgeAI

Annovis Bio (ANVS)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate...

Open: 1.380
High: 1.390
Low: 1.300
Prev. Close: 1.390
Volume: 1.69M
Turnover: 2.27M
Avg Price: 1.346
Bid/Ask Ratio: 56.90%
Amplitude: 6.47%
52wk High: 5.500
Volume Ratio: 3.47
Turnover Ratio: 4.78%

52wk Low: 1.300
Float Mkt Cap: 46.09M
Market Cap^USD: 55.60M
P/E^TTM: Loss
P/E^Dynamic: Loss
P/E^Static: --
EPS^TTM: -1.16
EPS^Dynamic: -1.52
EPS^Static: --
BVPS: -0.10
P/B: --
Circulating Supply: 35.32M
Dividend Yield^TTM: --
Dividend^TTM: --
Shares: 42.61M
Min lot size: 1
Currency: USD

Annovis Bio Analyst Rating

Forecast & Rating

Sep 8, 2026

Price forecast

$10.50704.60%

Forecast & RatingStrong buy

4analysts

Strong buy75.00%
Buy25.00%
Hold0.00%
Sell0.00%
Strong sell0.00%

Strong buy: 3
Buy: 1
Hold: 0
Sell: 0
Strong sell: 0

News

Market Beat · Sep 3 at 02:01 AM
Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA
PUBT · Aug 25 at 12:04 PM
Annovis Bio to host corporate update webinar with live Q&A session
PUBT · Aug 25 at 10:04 AM
Annovis Bio announces special shareholder meeting
Quartr · Aug 14 at 08:32 PM
ANVS: Alzheimer's Phase 3 trial fully enrolled; R&D costs and net loss per share increased year-over-year